Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
Feb 10, 2020
“Steve is an accomplished chemical engineer, scientist and executive with nearly 25 years of research and development experience in the life sciences industry, during which time he has led pipeline strategy and execution for multiple candidates, from discovery-stage through regulatory approval,” said
“Dicerna is one of only a handful of companies that is successfully harnessing RNAi to create new medicines that have the potential to prevent or interrupt the course of genetically linked diseases,” commented Dr. Doberstein. “The nonclinical and clinical success that Dicerna has achieved to date is very encouraging, and I believe the Company has only just begun to realize the potential of its GalXC RNAi technology platform. I am honored to join Dicerna’s board at this pivotal time of growth and progress at the Company, as it advances its lead candidate through late-stage development and prepares to transition to a commercial-stage biopharmaceutical company.”
Dr. Doberstein was named Chief Scientific Fellow at Nektar in
Prior to Nektar, Dr. Doberstein was Vice President of Research at
Dr. Doberstein received his bachelor’s degree in chemical engineering from the
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements relating to the future growth of the Company. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the
Dicerna™ and GalXC™ are trademarks of
Amy Trevvett, Dicerna Pharmaceuticals, Inc.
Alex Van Rees, SmithSolve
+1 973-442-1555 ext. 111
Lauren Stival, Stern Investor Relations, Inc.